Vielen Dank für Ihre Anfrage.
Wir werden Sie innerhalb weniger Werktage kontaktieren.
(Geschäftseinheit Performance Materials, Sales Support Team)
Gebäude AIA Central, Ebene 39, Jl. Jend. Sudirman Kav. 48A, Jakarta Selatan, Indonesien
+62 21 2988 8557
Erfolg! Ihre Anfrage wurde an unser Vertriebsteam übermittelt.
Etwas ist schiefgelaufen! Bitte versuchen Sie es später erneut.
Wir haben 26 Elemente gefunden.
| Kontaktdaten des Antragstellers | |
| Vollständiger Name | |
| Unternehmen | |
| Position | |
| Telefonnummer | |
| Geschäftliche E-Mail-Adresse | |
| Lieferadresse | |
Thank you. Your request has been sent.
Refarmed Chemicals presents Alacepril, a premium-grade antihypertensive medication catering to the pharmaceutical industry's mandate for efficacy and safety. This ACE (Angiotensin-converting enzyme) inhibitor is an integral pharmaceutical compound used in the treatment of hypertension and to mitigate the risk of myocardial infarction in patients with left ventricular dysfunction. By inhibiting ACE, Alacepril decreases the production of angiotensin II, resulting in vasodilation, reduced vascular resistance, and consequently, lower blood pressure. Constructed as a white crystalline powder, Alacepril is noted for its commendable solubility in methanol and ethanol (95%), with moderate solubility in water, facilitating its versatile use in different medicinal formulations. With quality as its cornerstone, Alacepril assures a high purity level, with an assay (by titration) confirming a 98.0% to 101.0% concentration for optimal therapeutic benefit. Each impurity is rigorously controlled to ≤ 0.2% and total impurities to ≤ 0.5%, ensuring compliance with robust pharmaceutical standards. Alacepril is packaged with comprehensive documentation, including DMF and JDMF certifications, and is produced under EU GMP guidelines, reflecting an unwavering commitment to regulatory conformance and product integrity. Precautionary measures are accounted for, with guidelines established for patients with hepatic or renal impairment, and contraindications identified for populations at risk, including during pregnancy and when potential for specific drug interactions exists. With a rapid absorption and an onset of action within 1-2 hours, Alacepril maintains its therapeutic efficacy for approximately 24 hours, making it a convenient once-daily treatment. Renal excretion serves as its primary elimination pathway, underscoring the need for tailored dose adjustments in patients with renal impairment. Trust Alacepril from Refarmed Chemicals for effective blood pressure management, anchored by our dedication to safety, efficacy, and quality control. Experience the synergy of cutting-edge pharmaceutical science and comprehensive patient care with Alacepril—a flagship example of our mission to support health and well-being.
Products still subject to third-party patent protection might be available solely for R&D purposes.